US2007014874A1PendingUtilityA1
Compositions for regenerating defective or absent myocardium
Assignee: CORMATRIX CARDIOVASCULAR INCPriority: Jul 15, 2005Filed: Jun 6, 2006Published: Jan 18, 2007
Est. expiryJul 15, 2025(expired)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61K 35/22A61L 2300/426A61L 2300/64A61L 27/3834A61L 2300/45A61K 38/1825A61L 2430/20A61L 2300/412A61L 2430/30A61K 35/34A61L 27/367A61L 2400/06A61K 9/0019A61K 35/38A61L 27/40A61L 27/3633A61L 2300/414A61L 27/3683A61L 27/58A61K 35/545A61K 31/7088A61L 27/3873A61K 38/39A61L 27/227A61K 35/50A61K 38/1841A61K 31/726A61K 38/1741A61L 27/3687A61K 35/37A61K 48/00A61L 27/3629A61L 27/54A61K 35/407A61K 35/28A61K 31/711A61K 31/7105A61L 27/3804
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.
Claims
exact text as granted — not AI-modified1 . A method of making an emulsified or injectable extracellular matrix composition from a mammalian or synthetic source comprising emulsifying a mammalian or synthetic extracellular matrix scaffold component from a mammalian or synthetic source and a first additional component selected from the group consisting of a collagen present in myocardial tissue, a collagen type IV protein, a collagen type VIII protein, a collagen type X protein, a multiplexin, a matrix heparin sulfate protoeglycan, a laminin, a nidogen, an agin, and a perlecan, and storing the composition as an emulsion for administration to a patient.
2 . The method as in claim 1 , further comprising adding a second additional component to the composition before, after or during emulsification.
3 . The method as in claim 2 , wherein the second additional component is selected from the group consisting of
a) a cell, b) a peptide, polypeptide, or protein, c) a vector having a DNA capable of targeted expression of a selected gene, and d) a nutrient, a sugar, a fat, a lipid, an amino acid, a nucleic acid, a ribo-nucleic acid, an organic molecule, an inorganic molecule, a small molecule, a drug, or a bioactive molecule.
4 . The method as in claim 1 wherein the emulsion comprises mammalian extracellular matrix selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS), collagen from animal sources, collagen from plant sources, synthesized extracellular matrix in cultures from cells (Matrigel™), dermal extracellular matrix material, subcutaneous extracellular matrix material, large intestine extracellular matrix material, placental extracellular matrix material, ornamentum extracellular matrix material, heart extracellular matrix material, and lung extracellular matrix material.
5 . The method as in claim 1 , wherein the emulsion comprises synthetic extracellular matrix selected from the group consisting of polyethylene terephthalate fiber (Dacron), polytetrafluoroethylene (PTFE), glutaraldehyde-cross linked pericardium, polylactate (PLA), polyglycol (PGA), hyaluronic acid, polyethylene glycol (PEG), polyethelene, a nucleic acid polymer, nitinol, and collagen from non-animal sources.Join the waitlist — get patent alerts
Track US2007014874A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.